TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT02375880

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: Administered by IV infusion.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: Administered by IV infusion
Study: NCT01950559

Intervention type: OTHER
Intervention: Oral food challenge
Description: Oral food challenge to determine allergy to soy
Study: NCT01064505

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: QPI-1007 at various doses
Description: Single Intravitreal Injection
Study: NCT01623206

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Desmopressin
Description: Dose groups: Group 1: 0.25 µg/kg/day; Group 2: 0.25 µg/kg/12 hours; Group 3: 0.50 µg/kg/12 hours; Group 4: 1 µg/kg/day; Group 5: 1 µg/kg/12 hours; Group 6: 2 µg/kg/day.~All groups will receive desmopressin intravenously, in a 15-20 minutes infusion, one or two times a day. The administration will be repeated 24 hours after the first infusion.
Study: NCT01886391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diaphragmatic Breathing Retraining
Description: Diaphragmatic breathing retraining (DBR) with a slow breathing pattern such that breathe in slowly through the nose for 4 seconds and breathe out slowly through the mouth for 6 seconds and mediated by Self-efficacy for DBR. Patients in this group will receive detailed instructions, in-person, as to how to carry out the DBR intervention at home. They will provide a return demonstration to the research staff about how to do the deep breathing. They will also receive a written script of the DBR intervention. In addition to the script, patients in this group will receive 3 audio CDs (1 for week 1 \[5-min DBR\], 1 for week 2 \[10-min DBR\], 1 for weeks 3-8 \[15-min DBR\]), developed by the PI, to use to practice their deep breathing.
Study: NCT01902381

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 6,8-bis(benzylthio)octanoic acid
Description: Given IV
Study: NCT02790359

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Air
Description: Group of patients who would receive air insufflation

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Carbon dioxide
Description: Group of patients who would receive carbon dioxide insufflation
Study: NCT01881997

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fentanyl
Description: Fentanyl Intramuscular (IM), 1ugm/kg, x1
Study: NCT00837096

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: V.A.C. Therapy
Description: Negative Pressure Wound Therapy (NPWT) distributes negative pressure across a wound base by means of a specially engineered dressing with the specific intent to help promote wound healing.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Moist wound therapy (MWT)
Description: Gauze Pads, Transparent Films, Hydrogels, Foam, Hydrocolloids, alginate, collagen, and antimicrobial
Study: NCT02394509

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Home Based Self-management and Cognitive Training Changes lives (HOBSCOTCH)
Description: HOBSCOTCH is a home-based self-management program to treat cognitive symptoms and improve quality of life, while minimizing the barriers of access to care. The program is based on Problem Solving Therapy (PST) and teaches problem solving strategies and compensatory mechanisms to help manage cognitive dysfunction and enhance quality of life.
Study: NCT01521689

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: Low doses of sub cutaneaous rituximab
Study: NCT04514796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Adalimumab
Description: SB5 (adalimumab), 40 mg, single-dose

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: SB5 (adalimumab), 40 mg, single-dose
Study: NCT00515697

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Ramucirumab is an injectable solution administered as an intravenous infusion over 1 hour at a dose of 8 mg/kg day 1 of every 14-day cycle.
Study: NCT01881997

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Normal Saline
Description: IM normal saline
Study: NCT03337581

Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Dexmedetomidine
Description: see arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: see arms
Study: NCT01111136

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Stress intervention
Description: To evaluate psychological stress, participants will complete the Perceived Stress Scale, Beck Depression Inventory-Fast Screen, Anxiety Sensitivity Index-III, Posttraumatic Stress Diagnostic Scale and the Depression Anxiety Stress Scales; to evaluate cognitive and behavioral aspects of emotional avoidance, participants will complete the Emotional Avoidance Questionnaire as well as the Acceptance and Action Questionnaire, Difficulties in Emotion Regulation Scale, Illness Attitudes Scale and the Five Facet Mindfulness Questionnaire; and to evaluate quality of life in regards to his/her skin condition, participants will complete the Dermatology Life Quality Index questionnaire.
Study: NCT03338257

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Husky Reads Intervention
Description: The Husky Reads curriculum now includes a series of 10 lessons designed to introduce preschool-age children to MyPlate while improving fruit and vegetable literacy. Each lesson includes reading at least one children's book, an activity or game, and food tasting to complement learning objectives related to MyPlate and fruit/vegetable literacy. Undergraduate students enrolled in the Husky Reads service- learning course at UConn or college students participating in the paid summer internship program deliver the preschool lessons. Each team of 2-3 undergraduate students is assigned 2-3 early care classrooms to visit and deliver Husky Reads lessons to on a weekly basis.
Study: NCT02160678

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: Cream Vehicle (placebo) (G \& W Laboratories, Inc.)- vehicle

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tazarotene Cream, 0.1 %
Description: Tazarotene Cream, 0.1 % (G \& W Laboratories, Inc.) - test product

Intervention type: DRUG
Group type: OTHER
Intervention: Tazorac Cream, 0.1%
Description: Tazorac Cream, 0.1% (Allergan, Inc.) - reference product
Study: NCT01565239

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fiix prothrombin time
Description: The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Fiix prothrombin time
Description: The Fiix prothrombin time (or Stuart-prothrombin time) is a new modification of the currently used prothrombin times. The Fiix PT as opposed to PT is sensitive to the activity of coagulation factors II and X only whereas the PT is sensitive to factors I, II, V, VII and X.
Study: NCT04493983

Intervention type: PROCEDURE
Group type: OTHER
Intervention: laparoscopic salpingo-oophorectomy
Description: Laparoscopic bilateral salpingo-oophorectomy

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Laparoscopic bilateral salpingo-oophorectomy
Description: Unilateral oophorectomy was performed immediately after abdominal entry, and the remaining contralateral ovary was excised at the end of the hysterectomy in order to compare the effect of these surgical procedures on ovarian tissue.
Study: NCT03337581

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: see arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: see arms

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: see arms
Study: NCT03805451

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Life Steps for PrEP for Youth
Description: Life-Steps is a modular adherence intervention based on principles of cognitive-behavioral therapy (CBT), that allows for recipients of the intervention to focus on the greatest challenges that they perceive in maintaining optimal adherence to pre-exposure prophylaxis.
Study: NCT04106050

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB095
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIB074
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered as specified in the treatment arm.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Administered as specified in the treatment arm.
Study: NCT03602391

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: SCP Plus
Description: The primary goal of the proposed project is to develop an in-home psychoeducational intervention (Senior Companion Program Plus, or SCP Plus) that is accessible, affordable, and sustainable for low-income African American ADRD caregivers. A weekly, 60 minute psychoeducational module will be delivered face-to-face across 9 weeks and will focus on education about ADRD, behavior management, communication skills, and aspects of providing care that enhance meaning such as spirituality. In order to provide an accessible intervention that is potentially sustainable, Senior Companions will be trained to provide the intervention in the homes of the African American ADRD caregivers.
Study: NCT03991013

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dolutegravir 50 mg
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a lead-in supplementary dose of 50 mg dolutegravir taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Study: NCT01928407

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DARUNAVIR
Description: The patient included will receive their first antiretroviral regimen included the darunavir treatment in combination with 2 others molecules

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATAZANAVIR
Description: The patient included will receive their first antiretroviral regimen included the atazanavir treatment in combination with 2 others molecules
Study: NCT03207620

Intervention type: DIAGNOSTIC_TEST
Intervention: using serum periostin and eotaxin-2 level
Description: collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.

Intervention type: DIAGNOSTIC_TEST
Intervention: using serum periostin and eotaxin-2 level
Description: collect serum sample from each group and detection of serum periostin and eotaxin-2 are using Eliza kits.~each group is divided into two groups (patients who are already using ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.

Intervention type: DIAGNOSTIC_TEST
Intervention: airway corticosteroid sensitivity
Description: each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.

Intervention type: DIAGNOSTIC_TEST
Intervention: airway corticosteroid sensitivity
Description: each group is divided into two groups (patients who are already using inhaled corticosteroid ICS and patients who do not use ICS) and we compare between to groups in airway hypersensitivity.
Study: NCT00111839

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pemetrexed
Description: Pemetrexed will be administered IV until PD or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matuzumab
Description: Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Matuzumab
Description: Matuzumab will be administered IV until PD or the occurrence of unacceptable toxicity.
Study: NCT01863537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Multimedia Connect

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Connect
Study: NCT03152500

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FEMTIS 313G IOL
Description: Haptic design that enclaves the capsulorrhexis

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Acrysof SN60WF IOL
Description: IOL in the bag
Study: NCT02867371

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Archimedes System
Description: The Archimedes System is an image-guided navigation system used to access tissue samples in the lungs
Study: NCT03753750

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Noninvasive spinal cord stimulation
Description: Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Noninvasive spinal cord stimulation
Description: Noninvasive spinal cord stimulation is a transcutaneous technique used to modulate the activity of the spinal cord. Subjects will undergo sham or actual stimulation 3-4 times a week for one hour at a time.
Study: NCT00397202

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Diva Cup TM
Description: See Detailed Description.
Study: NCT01494740

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted vaccine of 7.5 μg
Description: 120 infants were assigned to receive 2 dose of 7.5μg split-virion, non-adjuvanted H1N1 vaccine.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: split-virion, non-adjuvanted H1N1 vaccine of 15 μg
Description: 120 infants were assigned to receive 2 dose of 15μg split-virion, non-adjuvanted H1N1 vaccine.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: split-virion, non-adjuvanted vaccine of seasonal influenza
Description: 120 infants were assigned to receive 2 dose of split-virion, non-adjuvanted seasonal influenza vaccine.
Study: NCT03991013

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Tenofovir-lamivudine-dolutegravir fixed-dose combination tablet with a matching placebo taken 12 hours later for the first 14 days, with continuation of tenofovir-lamivudine-dolutegravir for the duration of the study (48 weeks).
Study: NCT02940093

Intervention type: OTHER
Intervention: Stem cell transplantation
Description: Intervention is not conducted as part of the study but patients at Tübingen University Hospital undergoing this intervention as part of their standard care are being monitored in this observational study.
Study: NCT03104400

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adalimumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Upadacitinib
Description: Oral tablet

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo to Adalimumab
Description: Administered by subcutaneous injection
Study: NCT05131087

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cadence implant
Description: CADENCE Glaucoma Drainage Device System is a single use implantable glaucoma drainage device used for the surgical treatment of refractory glaucoma. The device is implanted in the eye using an ab-externo approach
Study: NCT00242203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Zometa

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Epirubicin

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Trastuzumab
Description: ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trastuzumab
Description: ONLY for patients that are Her-2 overexpressing by 3+ by ICH for FSH

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: External beam radiation
Study: NCT02223507

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIIR 561 CL

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT00242203

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: External beam radiation

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Modified radical mastectomy or breast conserving surgery with axillary lymph node dissection
Study: NCT01421589

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Growth hormone treatment
Description: Growth hormone 0.4 mg once daily (titrated to IGF-1) by sub-cutaneous injection for 12 weeks.
Study: NCT03790514

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Heat Wrap
Description: Commercially heat tapes ( without drugs) will be applied to patients.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Wrap
Description: Commercially heat tapes ( without drugs) will be applied to patients.
Study: NCT01082172

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implant Thoracic Stent Graft
Description: Endovascular implant of Thoracic Aortic Aneurysm Stent Graft
Study: NCT04204772

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated charcoal and Tap Water
Description: 12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated charcoal and Tap Water
Description: 12 grams of AC mixed with Tap water or 25 grams of AC mixed with Tap water

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated Charcoal and Apple Juice
Description: 12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Activated Charcoal and Apple Juice
Description: 12 grams of AC with Apple Juice or 25 grams of AC with Apple Juice
Study: NCT02676323

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Panobinostat
Description: Panobinostat will be given orally (PO) on days 1, 3, 5, 8, 10, and 12.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: Fludarabine will be given intravenously (IV), 30 mg/m\^2/dose over 30 minutes, daily for 5 days (days 8-12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: Cytarabine will be given IV, 2 gram/m\^2/dose over 4 hours, daily for 5 days (days 8-12).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intrathecal Triples
Description: Given intrathecally (IT).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin (5 mg/m\^2/dose, max 5 mg) may be given PO or IV at 24 and 30 hours after each ITMHA.
Study: NCT00464919

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tegafur/uracil (UFUR®)